Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Imiglucerase in the treatment of Gaucher disease: a history and perspective.

Deegan PB, Cox TM.

Drug Des Devel Ther. 2012;6:81-106. doi: 10.2147/DDDT.S14395. Epub 2012 Apr 18. Review.

2.

Gaucher disease, enzyme replacement therapy, and the Patient Assistance Program.

Goldwater RS.

J Intraven Nurs. 1996 Mar-Apr;19(2):83-8. Erratum in: J Intraven Nurs 1996 May-Jun;19(3):158.

PMID:
8852168
3.

Why Genzyme can charge so much for Cerezyme.

Anand G.

Wall St J (East Ed). 2005 Nov 16:A15. No abstract available.

PMID:
16502533
4.

Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.

Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM.

Blood Cells Mol Dis. 2010 Jan 15;44(1):41-7. doi: 10.1016/j.bcmd.2009.09.006. Epub 2009 Oct 4.

PMID:
19804996
5.

Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.

Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M.

Blood Cells Mol Dis. 2011 Jan 15;46(1):107-10. doi: 10.1016/j.bcmd.2010.05.002. Epub 2010 Jun 1.

PMID:
20684886
6.

Individualization of long-term enzyme replacement therapy for Gaucher disease.

Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ; International Collaborative Gaucher Group U.S. Regional Coordinators.

Genet Med. 2005 Feb;7(2):105-10. Review. Erratum in: Genet Med. 2005 Sep;7(7):514. Prakesh-Cheng, Ainu [corrected to Prakash-Cheng, Ainu]. Genet Med. 2005 Jul-Aug;7(6):460.

PMID:
15714077
7.

Gaucher disease: clinical profile and therapeutic developments.

Cox TM.

Biologics. 2010 Dec 6;4:299-313. doi: 10.2147/BTT.S7582.

8.

The long-term international safety experience of imiglucerase therapy for Gaucher disease.

Starzyk K, Richards S, Yee J, Smith SE, Kingma W.

Mol Genet Metab. 2007 Feb;90(2):157-63. Epub 2006 Oct 31.

PMID:
17079176
9.

Imiglucerase and its use for the treatment of Gaucher's disease.

Weinreb NJ.

Expert Opin Pharmacother. 2008 Aug;9(11):1987-2000. doi: 10.1517/14656566.9.11.1987 . Review.

PMID:
18627336
10.

Imiglucerase treatment in Gaucher's disease.

Shah U, Nadeem N, Husen Y, Fadoo Z.

J Ayub Med Coll Abbottabad. 2007 Apr-Jun;19(2):56-9.

PMID:
18183722
11.

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.

Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO.

Ann Intern Med. 1995 Jan 1;122(1):33-9.

PMID:
7985893
12.

Velaglucerase alfa for the management of type 1 Gaucher disease.

Morris JL.

Clin Ther. 2012 Feb;34(2):259-71. doi: 10.1016/j.clinthera.2011.12.017. Epub 2012 Jan 20. Review.

PMID:
22264444
13.

Management of Gaucher disease in a post-communist transitional health care system: Croatian experience.

Mrsić M, Stavljenić-Rukavina A, Fumić K, Labar B, Bogdanić V, Potocki K, Kardum-Skelin I, Rovers D.

Croat Med J. 2003 Oct;44(5):606-9.

14.

A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.

Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ.

Mol Genet Metab. 2009 Apr;96(4):164-70. doi: 10.1016/j.ymgme.2008.12.015. Epub 2009 Feb 4.

PMID:
19195916
15.

Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.

Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C.

J Inherit Metab Dis. 2013 May;36(3):543-53. doi: 10.1007/s10545-012-9528-4. Epub 2012 Sep 14. Erratum in: J Inherit Metab Dis. 2014 Jan;37(1):147.

16.

The cost of treating Gaucher disease.

Beutler E.

Nat Med. 1996 May;2(5):523-4. No abstract available.

PMID:
8616707
17.

Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.

Séllos-Moura M, Barzegar S, Pan L, Shi P, Oommen S, Durant J, Ruiz JA.

J Immunol Methods. 2011 Oct 28;373(1-2):45-53. doi: 10.1016/j.jim.2011.07.020. Epub 2011 Aug 6.

18.

The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.

Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A, Giralt M, Heitner R, Hollak C, Hrebicek M, Lewis S, Mehta A, Pastores GM, Rolfs A, Miranda MC, Zimran A; Advisory Council to the European Working Group on Gaucher Disease.

J Inherit Metab Dis. 2003;26(6):513-26. Review.

PMID:
14605497
19.

Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease.

Erdoğdu D, Gelincik A, Canbaz B, Colakoğlu B, Büyüköztürk S, Tanakol R.

Int Arch Allergy Immunol. 2013;160(2):215-7. doi: 10.1159/000339754. Epub 2012 Sep 25.

PMID:
23018845
20.

[Gaucher's disease and imiglucerase in 2009/2010: what leads to a suddenly enforced prioritisation?].

Hofstetter K, Raspe H, Stumpf S, Framke S.

Gesundheitswesen. 2015 Feb;77(2):86-92. doi: 10.1055/s-0034-1370997. Epub 2014 Mar 26. German.

PMID:
24671892
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk